15W103: Late-Breaking Abstracts (L15–L20)

Presenting Author(s)

• FH

  Fareeda Hosein, MD, MBA

  BMS
  Summit, NJ, United States

  Disclosure information not submitted.
• DH

  David Hunter, PhD, MBBS, FRACP

  Sydney Musculoskeletal Health, University of Sydney
  St Leonards, New South Wales, Australia

  Disclosure information not submitted.
• RK

  Robert Keenan, MD, MPH, MBA

  Arthrosi Therapeutics
  Chapel Hill, NC, United States

  Disclosure information not submitted.
• LP

  Linyi Peng, n/a (she/her/hers)

  Peking Union Medical College Hospital，Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases
  Beijing, Beijing, China (People's Republic)

  Disclosure information not submitted.
• HX

  Huji Xu, n/a

  Department of Rheumatology and Immunology, Changzheng Hospital, Naval Medical University
  Shanghai, China

  Disclosure information not submitted.
• QZ

  Qing Zuraw, MD, MPH, MBA

  RemeGen Biosciences
  Wayne, PA, United States

  Disclosure information not submitted.

Abstract oral session.

Non-CME

Presentations:

• 7:30 AM – 7:45 AM PT

  AR882, an Efficacious and Selective URAT1 Inhibitor for Patients with Chronic Gouty Arthritis and Subcutaneous Tophi: Results from a Global, Prospective, Proof-of-Concept Trial Using Dual Energy Computed Tomography
  

  Presenting Author: Robert T. Keenan, MD, MPH, MBA – Arthrosi Therapeutics
• 7:45 AM – 8:00 AM PT

  Withdrawal of Immunosuppressant and Low-dose Steroids in IgG4-RD Patients with Stable Disease (WInS IgG4-RD): An Investigator-initiated, Multi-center, Open-label, Randomized Controlled Trial
  

  Presenting Author: Linyi Peng, n/a (she/her/hers) – Peking Union Medical College Hospital，Department of Rheumatology and Clinical Immunology, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases
• 8:00 AM – 8:15 AM PT

  Safety, Tolerability, and Exploratory Efficacy of Afimetoran, a TLR7/8 Inhibitor, in Patients with Cutaneous Lupus Erythematosus: A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study
  

  Presenting Author: Fareeda Hosein, MD, MBA – BMS
• 8:15 AM – 8:30 AM PT

  Immune-metabolic Heterogeneity and Clinical Implications in Primary Sjogren's Syndrome Revealed by Molecular Classification of Salivary Glands
  

  Presenting Author: Huji Xu, n/a – Department of Rheumatology and Immunology, Changzheng Hospital, Naval Medical University
• 8:30 AM – 8:45 AM PT

  A Phase 3 Study of Repeat Injection of TLC599 in Osteoarthritis of the Knee: Benefits to 52 Weeks
  

  Presenting Author: David Hunter, PhD, MBBS, FRACP – Sydney Musculoskeletal Health, University of Sydney
• 8:45 AM – 9:00 AM PT

  Telitacicept, a Human Recombinant Fusion Protein Targeting and Neutralizing B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), in Rheumatoid Arthritis (RA) Patients with an Inadequate Response to Methotrexate (MTX): A Randomized, Double-Blind, Phase 3 Study
  

  Presenting Author: Qing Zuraw, MD, MPH, MBA – RemeGen Biosciences